ArticleJournal of family medicine and primary care
Nipah virus epidemic in southern India and emphasizing "One Health" approach to ensure global health security.
Article in Journal of family medicine and primary care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Hendra and Nipah viruses: Biosafety evidence for risk-based containment, inactivation practices, and one health preparedness.One health (Amsterdam, Netherlands) · 2026Review
- Nipah Virus: A Neurotropic Zoonosis-From Molecular Biology to Clinical Manifestations and Translational Advances.Viruses · 2026Review
- The Nipah virus threat in India: Epidemiological trends, risk drivers, and lessons for pandemic preparedness.PLoS pathogens · 2026Review
- Article
- Nipah Virus: A Zoonotic Threat Re-Emerging in the Wake of Global Public Health Challenges.Microorganisms · 2025Review
- Optimal control analysis for the transmission of Nipah infection with imperfect vaccination.PloS one · 2025Article
- Uncovering human kinase substrates in nipah proteome.Frontiers in bioinformatics · 2025Article
- Nipah virus resurgence: a call for preparedness across states.Infectious medicine · 2024Article
- Optimal control analysis for the Nipah infection with constant and time-varying vaccination and treatment under real data application.Scientific reports · 2024Article
- Development and evaluation of a quadruple real-time fluorescence-based quantitative reverse transcription polymerase chain reaction assay for detecting Langya, Mojiang, Nipah, and Cedar viruses.Biosafety and health · 2024Article
- Recurrent Nipah outbreaks in Kerala: implications for health policy and preparedness.Frontiers in public health · 2024Article
- Nipah Virus: An Overview of the Current Status of Diagnostics and Their Role in Preparedness in Endemic Countries.Viruses · 2023Review
- Review
- Possible high risk of transmission of the Nipah virus in South and South East Asia: a review.Tropical medicine and health · 2023Review
- Evaluation of therapeutic potentials of selected phytochemicals against Nipah virus, a multi-dimensional in silico study.3 Biotech · 2023Article
- One Health activities to reinforce intersectoral coordination at local levels in India.Frontiers in public health · 2023Review
- Pangenomic and immunoinformatics based analysis of Nipah virus revealed CD4Frontiers in pharmacology · 2023Article
- A short communication of Nipah virus outbreak in India: An urgent rising concern.Annals of medicine and surgery (2012) · 2022Article
- Computational Identification of Potential Multitarget Inhibitors of Nipah Virus by Molecular Docking and Molecular Dynamics.Microorganisms · 2022Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV) encephalitis first reported in "Sungai Nipah" in Malaysia in 1999 has emerged as a global public health threat in the Southeast Asia region. From 1998 to 2018, more than 630 cases of NiV human infections were reported. NiV is transmitted by zoonotic (from bats to humans, or from bats to pigs, and then to humans) as well as human-to-human routes. Deforestation and urbanization of some areas have contributed to greater overlap between human and bat habitats resulting in NiV outbreaks. Common symptoms of NiV infection in humans are similar to that of influenza such as fever and muscle pain and in some cases, the inflammation of the brain occurs leading to encephalitis. The recent epidemic in May 2018 in Kerala for the first time has killed over 17 people in 7 days with high case fatality and highlighted the importance of One Health approach. The diagnosis is often not suspected at the time of presentation and creates challenges in outbreak detection, timely control measures, and outbreak response activities. Currently, there are no drugs or vaccines specific for NiV infection although this is a priority disease on the World Health Organization's agenda. Antivirals (Ribavirin, HR2-based fusion inhibitor), biologicals (convalescent plasma, monoclonal antibodies), immunomodulators, and intensive supportive care are the mainstay to treat severe respiratory and neurologic complications. There is a great need for strengthening animal health surveillance system, using a One Health approach, to detect new cases and provide early warning for veterinary and human public health authorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.